购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

INCB3344

产品编号 TQ0103Cas号 1262238-11-8

INCB3344 是一种有效、特异性和口服生物可利用的 CCR2 拮抗剂,结合拮抗作用的 IC50 值为 9.5 nM (mCCR2) 和 5.1 nM (hCCR2),趋化活性拮抗作用的 IC50 值为 7.8 nM (mCCR2) 和 3.8 nM (hCCR2)。

INCB3344

INCB3344

纯度: 98.2%
产品编号 TQ0103Cas号 1262238-11-8

INCB3344 是一种有效、特异性和口服生物可利用的 CCR2 拮抗剂,结合拮抗作用的 IC50 值为 9.5 nM (mCCR2) 和 5.1 nM (hCCR2),趋化活性拮抗作用的 IC50 值为 7.8 nM (mCCR2) 和 3.8 nM (hCCR2)。

规格价格库存数量
1 mg¥ 565现货
5 mg¥ 1,320现货
10 mg¥ 2,150现货
25 mg¥ 3,620现货
50 mg¥ 5,160现货
100 mg¥ 6,950现货
200 mg¥ 9,560现货
1 mL x 10 mM (in DMSO)¥ 1,580现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"INCB3344"的相关化合物库

选择批次:
纯度:98.2%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
INCB3344 is an effective, specific and orally bioavailable CCR2 antagonist with IC50 values of 9.5 nM (mCCR2) and 5.1 nM (hCCR2) in binding antagonism and 7.8 nM (mCCR2) and in 3.8 nM (hCCR2) antagonism of chemotaxis activity.
靶点活性
CCR2 (mouse):9.5 nM, CCR2 (human):5.1 nM
体外活性
INCB3344的药理活性首先通过利用小鼠单核细胞系WEHI-274.1,通过全细胞结合试验,评估其抑制CCL2与CCR2结合的能力来进行表征。在该试验中,INCB3344的结合IC50被确定为10 nM,而在90 nM的浓度下观察到>90%的结合抑制[1]。INCB3344还是对大鼠和猕猴CCR2的有效拮抗剂,其结合拮抗IC50值分别为7.3和16 nM,化学趋化活性拮抗的IC50值分别为2.7和6.2 nM。此外,INCB3344对超过50种离子通道、转运蛋白、趋化因子受体及其他选定的GPCRs展示出>1 μM的IC50值。它也是一种选择性的mCCR2拮抗剂,对最与mCCR2同源的两种趋化因子受体,即murine CCR1和murine CCR5表现出>1 μM和>3 μM的IC50值[4]。
体内活性
INCB3344能够防止去氧皮质酮醋酸酯(DOCA)/盐诱导的血管CCR2表达变化。在一系列独立实验中,从DOCA/盐处理周期的第7天到第21天接受INCB3344的小鼠主动脉中CCR2表达提高约1.5倍,与安慰剂动物相比明显较低;但是,这一CCR2表达水平显著低于仅接受载体处理组的水平。同样,接受INCB3344的小鼠中DOCA/盐处理引起的其受体配体CCL2表达增加被减弱。相比之下,接受载体或INCB3344的DOCA/盐处理小鼠中CCL7、CCL8和CCL12的水平均有类似程度的提高[2]。通过静脉给药给CD-1小鼠时,INCB3344表现出高清除率和适中的分布体积,导致半衰期短,仅为1小时。尽管清除率高,但通过口服给药仍能获得良好的暴露效果,10 mg/kg剂量的AUC为2664 nM h。口服生物利用度为47%。相比之下,以相同剂量口服给Balb/c小鼠时获得略好的口服暴露(AUC=3888 nM h)[4]。
激酶实验
Cells (5×10^5) in RPMI 1640 (VWR), +0.1% BSA+20 mM HEPES (VWR), are added to various concentrations of INCB3344 in RPMI 1640 followed immediately by the addition of 150 pM 125I-labeled mCCL2 (mouse CCL2(JE)) and incubated for 30 min at room temperature (RT). For the nonspecific control, 0.3 μM mCCL2 is added in place of INCB3344. Cells are then harvested through 1.2-μm polyvinylidene difluoride filters, the filters are air-dried, and binding is determined by counting in a gamma counter. Antagonist activity is reported as the inhibitor concentration required for IC50 of specific binding. Specific binding is defined as the total binding minus the nonspecific binding and typically represents 97% of the total binding [2].
细胞实验
WEHI-274.1 cells (5×10^5) in RPMI 1640 (VWR) with or without various concentrations of INCB3344 in RPMI 1640 are loaded in the wells on top of an 8-μm polycarbonate filter in a 96-well-modified Boyden chamber. Beneath the filter, 30 nM mCCL2 with or without INCB3344 or media is placed in a corresponding 96-well plate. The sealed chambers are incubated for 45 min at 37°C, 5% CO2. Filters are washed, stained with Wright-Giemsa, and the number of cells that migrate toward mCCL2 in the bottom chamber counted by microscopy. The ability of INCB3344 to antagonize CCR2-mediated chemotaxis is reported as the inhibitor concentration required for IC50 values of specific migration to mCCL2. Specific migration is defined as the total migration minus the background migration. A similar assay is used to determine the impact of INCB3344 on CCR1-mediated chemotaxis of WEHI-274.1 cells, by using mouse MIP-1α as a ligand. In addition C5a, FMLP and RANTES are similarly tested in the presence of INCB3344 for migration of WEHI-274.1 cells. For the studies on the impact of INCB3344 on CCR5-mediated chemotaxis, murine T cells are used as the cell system with mouse MIP-1β as the ligand [2].
动物实验
In a subset of experiments, DOCA/salt-treated mice are further randomly assigned to receive the CCR2 antagonist, INCB3344 (30 mg/kg per day) or vehicle (10% DMSO/0.9% carboxymethylcellulose) via daily intraperitoneal injections commencing 10 days after induction of hypertension and continuing until the end of the 21-day treatment period. The normotensive control group for these experiments consists of sham-treated mice that receive a vehicle from days 10 to 21 [3]. Adult male Sprague-Dawley rats (200-250 g) are used. After t=0 baseline measurement, rats are lightly anesthetized under an isoflurane/oxygen (5%; 2 L/min) flow and 25 μL of either saline (vehicle), 1 μg of CCL2 and/or 1 mM of INCB3344 is administered intrathecally between L5 and L6 vertebrae. Animals are tested once at 30, 60, 90, 120, and 240 min following drug administration. The percentage of maximal potential effect is calculated for every time point [4].
化学信息
分子量577.59
分子式C29H34F3N3O6
CAS No.1262238-11-8
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
H2O: Insoluble
DMSO: 210 mg/mL (363.58 mM), Sonication is recommended.
溶液配制表
DMSO
1mg5mg10mg50mg
1 mM1.7313 mL8.6567 mL17.3133 mL86.5666 mL
5 mM0.3463 mL1.7313 mL3.4627 mL17.3133 mL
10 mM0.1731 mL0.8657 mL1.7313 mL8.6567 mL
20 mM0.0866 mL0.4328 mL0.8657 mL4.3283 mL
50 mM0.0346 mL0.1731 mL0.3463 mL1.7313 mL
100 mM0.0173 mL0.0866 mL0.1731 mL0.8657 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

Related Tags: buy INCB3344 | purchase INCB3344 | INCB3344 cost | order INCB3344 | INCB3344 chemical structure | INCB3344 in vivo | INCB3344 in vitro | INCB3344 formula | INCB3344 molecular weight